Stock DNA
Pharmaceuticals & Biotechnology
EUR 16 Million ()
NA (Loss Making)
NA
0.00%
-0.22
-5.68%
1.10
Revenue and Profits:
Net Sales:
11 Million
(Quarterly Results - Dec 2024)
Net Profit:
2 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
5.49%
0%
5.49%
6 Months
8.03%
0%
8.03%
1 Year
7.82%
0%
7.82%
2 Years
-51.1%
0%
-51.1%
3 Years
68.65%
0%
68.65%
4 Years
60.6%
0%
60.6%
5 Years
-9.88%
0%
-9.88%
Biofrontera AG for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-6.78%
EBIT Growth (5y)
14.52%
EBIT to Interest (avg)
-2.18
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.14
Sales to Capital Employed (avg)
1.07
Tax Ratio
55.43%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
1.45%
ROCE (avg)
7.72%
ROE (avg)
11.71%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.87
EV to EBIT
-2.32
EV to EBITDA
-2.70
EV to Capital Employed
0.85
EV to Sales
0.64
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-36.76%
ROE (Latest)
-23.07%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Mar 2021
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (1.45%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQ
Dec'24
Sep'24
Change(%)
Net Sales
10.90
3.50
211.43%
Operating Profit (PBDIT) excl Other Income
-0.20
-0.90
77.78%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
1.90
-0.90
311.11%
Operating Profit Margin (Excl OI)
-36.30%
-318.40%
28.21%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2024 is 211.43% vs 0.00% in Sep 2024
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2024 is 311.11% vs 65.38% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
21.70
32.20
-32.61%
Operating Profit (PBDIT) excl Other Income
-5.10
5.60
-191.07%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-4.30
-0.40
-975.00%
Operating Profit Margin (Excl OI)
-274.30%
148.30%
-42.26%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -32.61% vs 25.29% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -975.00% vs 99.10% in Dec 2023
About Biofrontera AG 
Biofrontera AG
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






